GlassScriptPhysician profile
Anne Nelson Walton
NPI 1902834997
$1,059.04
in general payments reported to CMS, 2019-2025
25 companies · $44.44 in 2025
The $44.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $29.07 · 2022: $176 · 2023: $194 · 2024: $270 · 2025: $44.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479 · Education: $29.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.21 |
| Education | $29.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $182.22 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $130.99 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $89.32 | 2019-2024 | Mounjaro, Zepbound |
| Amgen INC. | $68.26 | 2019-2023 | Otezla, Repatha |
| Ironshore Pharmaceuticals INC. | $65.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.57 | 2019-2024 | Eohilia |
| Merck Sharp & Dohme LLC | $54.16 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $50.51 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $40.12 | 2019 | |
| Astellas Pharma US INC | $33.30 | 2024 | Veozah |
| Exact Sciences Corporation | $29.94 | 2025 | The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $25.21 | 2024 | |
| Sanofi Pasteur INC. | $23.80 | 2023 | |
| Genentech USA, INC. | $23.40 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $22.12 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.81 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.37 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.06 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $16.64 | 2019 | |
| Amarin Pharma, INC. | $16.42 | 2019 | |
| Pfizer INC. | $16.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.88 | 2022 | |
| Glaxosmithkline, LLC. | $12.65 | 2019 | |
| Seqirus USA INC | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.